Goodwin’s IP litigation team secured a trial victory for Actavis Laboratories, paving the way for Actavis to launch a generic version of Quillivant®, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). Following the trial in federal district court in Delaware in February 2017, Judge Gregory Sleet entered judgment in Actavis’ favor, finding that Actavis had established by clear and convincing evidence that all five patents are invalid as obvious. The victory knocked out five patents that covered Quillivant® and that would have protected the drug from generic competition for another 14 years.
Actavis Laboratories is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high-quality affordable generic and innovative branded pharmaceutical products for patients around the world.
The Goodwin team was led by partner Elizabeth Holland and included partners Michael Cottler and William James; and associates Linnea Cipriano, Sarah Fischer, Alexandra Valenti, Molly Grammel, Tiffany Mahmood and Jennifer Ford.